Immunephenotype of baseline metastatic but not matched primary #urothelialcarcinoma identified durable ICI responders-PD-L1 status,spatial immunephenotype & MHC-I status provide complementary information-Markus Eckstein-comment Tim Clinton prac.co/l/2oxo4hgh @practiceupdate

2022 Top Story in #bladdercancer: Intravesical IL-15 superagonist (NAI)+BCG for BCG-Unresponsive non-muscle-invasive #bladdercancer-Durable complete response in 45% at 12 mo Sam S. Chang MD, MBA Dr. Pat Soon-Shiong-commentary by Matthew Mossanen prac.co/l/2qfctabv @practiceupdate

🙌 We are thrilled to officially launch Advances in Urologic Care 2023! This year's event will take place at Club Med Miches from November 11 to 18, 2023.🌴 🌎 urologiccare.com Hosted by Brigham and Women's Hospital Department of Urology x Harvard Medical School

🙏 to Matthew Mossanen for spearheading such an amazing wellness event for Brigham and Women's Hospital Department of Urology #wellness #healthyliving #teamworkmakesthedreamwork

Get ready for an extraordinary event in the breathtaking setting of #ClubMedMiches. Enhance your skills, network with experts, and relax in paradise. 🌴Limited spots available, book now to secure your place! 🌎urologiccare.com #AUC2023 #UrologyConference Brigham and Women's Hospital Department of Urology

Thank you Brigham and Women's Hospital for highlighting Advances in Urologic Care in the Dominican Republic. Join the 150+ already registered for the second edition featuring Brigham and Women's Hospital Department of Urology faculty + Cheryl Lee Mike Leveridge LoriLernerUro Matthew Mossanen brighamhealthonamission.org/2023/08/28/bri…

The complex case of a 46-year-old smoker with high-grade T1 #BladderCancer - Matthew Mossanen is joined by Jennifer Yates and Kent Mouw to discuss a patient case, emphasizing the importance of a multidisciplinary approach > bit.ly/3rQ4e4n Pfizer Inc. UMass Boston Dana-Farber

Video in UroToday.com: The Complex Case of a 46-Year-Old Smoker with High-Grade T1 Bladder Cancer - Jennifer Yates, Matthew Mossanen, and Kent Mouw. Click here to watch: urotoday.com/video-lectures…

We started the first treatment for our one-of-a-kind bladder cancer-specific nanoparticle Ph I trial. We did all the GMP, IND and other works by ourselves. Thank Kit Lam, Yuanpei Li Lab, JD Garisto, MD, Lucky Lara and many others. Submitting IND for a 2nd drug now. More to come.

To kick off Advances in Urologic Care — Matthew Mossanen takes center stage to introduce our keynote speakers Nature Reviews Urology #AUC2023

Cutting edge talk by Cheryl Lee on advancing care through clinical trials. Thank you for joining us at Advances in Urologic Care hosted by Brigham and Women's Hospital Department of Urology

Options to measure urine flow outside of the clinic. Important talk by LoriLernerUro on the management of BPH. Advances in Urologic Care Brigham and Women's Hospital Department of Urology

Prostate cancer and biomarkers — a rapidly changing landscape, says Adam Kibel at Advances in Urologic Care

Masterclass by Matthew Mossanen on the management of non invasive bladder cancer in the plenary of Advances in Urologic Care

Cystectomy can be a nightmare procedure for patients. At #AUC23, Matthew Mossanen discusses options to optimize outcomes in RC

“No side effects whatsoever.” Treatment #2 of the first-in-human Phase I trial of our novel bladder cancer-specific nanoparticle today. Thank JD Garisto, MD for the great work! Thank Matthew Mossanen for working on opening this trial Brigham and Women's Hospital

Many thanks to Advances in Urologic Care for a great meeting in the DR! ☀️Great speakers and perfect weather! And always fun catching up with #urology pals! Adam Kibel Quoc-Dien Trinh, MD, MBA Matthew Mossanen

.Cheryl Lee was the first Black woman in the country to lead a urology department. Mentoring trainees, medical students and junior faculty members, she hopes to inspire others to follow her into leadership roles. #WomenInScience health.osu.edu/health/cancer/…

1/ JUST IN: an 8 year #kidneycancer journey now published in nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author David Braun Yale Cancer Center and #PatrickOtt #DerinKeskin

Thoroughly enjoyed my day and conversations at Dana-Farber Lank Center for Genitourinary Oncology Kent Mouw Atish Choudhury, MD PhD Stephanie Berg Matthew Mossanen joaquim bellmunt Eli Van Allen Toni Choueiri, MD discussing the latest in #bladdercancer research and clinical trials. Thank you for the invitation and your hospitality!